Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity.
The clinicopathological roles of aurora kinase protein have not been studied in depth in colorectal cancer. The aim of the present study was to investigate the clinicopathological roles of aurora kinase protein expression in a large cohort of patients with colorectal adenocarcinoma with tight methodology and close follow-up. Aurora kinase protein expression was investigated in 200 patients (110 men, 90 women) with colorectal adenocarcinomas by immunohistochemistry. The findings were correlated with the clinicopathological features, p16 expression, and telomerase activity of colorectal adenocarcinomas. Aurora kinase protein was detected in 48.5% (97/200) of patients with colorectal carcinoma. The protein was more frequently detected in patients with well or moderately differentiated colorectal carcinomas than in poorly differentiated colorectal adenocarcinomas (52% versus 31%, P = .004). Mucinous adenocarcinomas were less often positive for the protein (16% versus 56%, P = .0001). Aurora kinase protein expression was more commonly seen in carcinomas in the rectum, sigmoid, and descending colon than in the proximal colon (55% versus 36%, P = .01). Also, aurora kinase protein expression was related to the expression of p16 protein (P = .001) and correlated inversely with the level of telomerase activity in colorectal carcinomas (P = .005). To conclude, aurora kinase protein is expressed in a subset of colorectal carcinoma. The expression of aurora kinase protein was found to be related to the distal location, grade of tumor, p16 expression, and telomerase activity. These findings may be important to select patients to benefit for clinical trials of aurora kinase inhibitors.
Lam
Alfred King-Yin
AK
Division of Pathology, School of Medicine, Griffith Medical School, Griffith University Gold Coast Campus, Gold Coast, Queensland 4222, Australia. a.lam@griffith.edu.au
Ong
Kate
K
Ho
Yik-Hong
YH
D000230:Adenocarcinoma / Q000201:enzymology* / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D064127:Aurora Kinases; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000032:analysis / Q000378:metabolism*; D019098:Telomerase / Q000032:analysis / Q000378:metabolism
D019941:Cyclin-Dependent Kinase Inhibitor p16; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases; C509186:TERT protein, human; D019098:Telomerase